Enviomycin
Star0
Identification
- Generic Name
- Enviomycin
- DrugBank Accession Number
- DB08993
- Background
Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 685.69
Monoisotopic: 685.325584661 - Chemical Formula
- C25H43N13O10
- Synonyms
- Enviomicina
- Enviomycin
- Enviomycine
- Enviomycinum
- Tuberactinomycin N
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Enviomycin is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Articaine. Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Enviomycin. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enviomycin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Enviomycin sulfate 67846BXW65 53760-33-1 DZKQVWCTFCSEKF-QOEBQMAPSA-N - International/Other Brands
- Tuberactin (Asahi Kasei Pharma)
Categories
- ATC Codes
- J04AB06 — Enviomycin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Cyclic peptides
- Alternative Parents
- Diazinanes / 1,3-aminoalcohols / Cyclic carboximidic acids / Secondary alcohols / 1,2-aminoalcohols / Guanidines / Isoureas / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Carboximidamides show 6 more
- Substituents
- 1,2-aminoalcohol / 1,3-aminoalcohol / 1,3-diazinane / Alcohol / Aliphatic heteromonocyclic compound / Amine / Azacycle / Carboximidamide / Carboximidic acid / Carboximidic acid derivative show 19 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Mycobacterium tuberculosis
Chemical Identifiers
- UNII
- XU299C23A2
- CAS number
- 33103-22-9
- InChI Key
- HPWIIERXAFODPP-GHBBWTPBSA-N
- InChI
- InChI=1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
- IUPAC Name
- (3R,4R)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-15-yl]-4-hydroxyhexanamide
- SMILES
- [H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O
References
- Synthesis Reference
U.S. Patent 3,892,732.
- General References
- Not Available
- External Links
- KEGG Drug
- D07897
- PubChem Compound
- 20055267
- PubChem Substance
- 310264954
- ChemSpider
- 16736480
- ChEMBL
- CHEMBL2146142
- ZINC
- ZINC000169291448
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Enviomycin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.56 mg/mL ALOGPS logP -3.5 ALOGPS logP -12 Chemaxon logS -2.4 ALOGPS pKa (Strongest Acidic) 8.71 Chemaxon pKa (Strongest Basic) 10.52 Chemaxon Physiological Charge 3 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 15 Chemaxon Polar Surface Area 392.86 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 161.87 m3·mol-1 Chemaxon Polarizability 65.92 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 242.73701 predictedDeepCCS 1.0 (2019) [M+H]+ 244.46071 predictedDeepCCS 1.0 (2019) [M+Na]+ 250.75163 predictedDeepCCS 1.0 (2019)
Drug created at June 16, 2014 15:39 / Updated at December 02, 2023 07:01